Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.

Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015 Apr 01; 33(10):1180-5.

View in: PubMed

subject areas

Adult
Adult
Aged
Aged
Anemia
Anemia
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Bevacizumab
Deoxycytidine
Deoxycytidine
Disease-Free Survival
Disease-Free Survival
Double-Blind Method
Double-Blind Method
Female
Female
Humans
Humans
Kaplan-Meier Estimate
Kaplan-Meier Estimate
Leiomyosarcoma
Leiomyosarcoma
Middle Aged
Middle Aged
Neoplasm Metastasis
Neoplasm Metastasis
Taxoids
Taxoids
Thrombocytopenia
Thrombocytopenia
Time Factors
Time Factors
Treatment Outcome
Treatment Outcome
Uterine Neoplasms
Uterine Neoplasms

authors with profiles

Robert S Mannel